BiotechTube
SapiensBio

SapiensBio

San Diego, United States· Est.
sapiensbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

SapiensBio is a preclinical-stage biotech utilizing its AI platform, Sapientia, for novel drug discovery, with a focus on idiopathic pulmonary fibrosis. Its lead candidate, SBC101, has received positive FDA Pre-IND feedback and is preparing for Phase 1 trials. The company is actively pursuing licensing deals and investment, positioning itself at a key inflection point as it transitions into clinical development.

Idiopathic Pulmonary Fibrosis

Technology Platform

Sapientia, a proprietary AI-driven platform for novel target discovery and clinical candidate development.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The primary opportunity is addressing the large, unmet medical need in Idiopathic Pulmonary Fibrosis with a first-in-class therapy.
Positive Phase 1 data could trigger lucrative licensing deals with global pharma companies.
The AI platform also offers potential to generate additional pipeline assets.

Risk Factors

High risk of clinical failure for its novel ARPC2 mechanism.
As a private, pre-revenue company, it faces significant funding and liquidity risks.
It also carries concentration risk with its value heavily tied to a single lead program.

Competitive Landscape

IPF treatment is dominated by two approved anti-fibrotics (pirfenidone, nintedanib) with limited efficacy. The competitive landscape includes other biotechs exploring novel pathways (e.g., autophagy, cellular senescence). SapiensBio's differentiation lies in its novel ARPC2 target, but it will need to demonstrate clinical superiority or a better safety profile.

More companies in AI / Machine Learning →More companies in United States →